Loading organizations...
UNITY Biotechnology develops therapeutics designed to selectively eliminate senescent cells, which accumulate with age and contribute to various age-related diseases. The company's scientific approach centers on the idea that clearing these dysfunctional cells can prevent, halt, and potentially reverse the progression of conditions such as osteoarthritis and certain ophthalmic diseases, thereby aiming to extend a healthy lifespan. Their pipeline focuses on small molecule inhibitors targeting pro-survival pathways in senescent cells.
The company was founded on the scientific insights of Judith Campisi, Jan van Deursen, Nathaniel David, and Daohong Zhou, with its foundational science emerging in 2009 and the corporate entity incorporated in 2011. These scientific pioneers recognized the significant role of cellular senescence in the aging process and chronic diseases, leading them to form UNITY with the ambitious goal of translating this understanding into novel pharmaceutical interventions. Their collective expertise provided the scientific bedrock for the company's anti-senescence drug development programs.
UNITY Biotechnology targets patients suffering from chronic age-related diseases that lack effective treatments, initially concentrating on areas like degenerative eye conditions and musculoskeletal disorders. The company's vision is to pioneer a new class of medicines that address the fundamental biological drivers of aging, moving beyond symptomatic relief to slow or reverse disease progression at its root. They aspire to make a significant impact on healthspan, enabling people to live longer, healthier lives.
UNITY Biotechnology has raised $212.0M across 4 funding rounds.
UNITY Biotechnology has raised $212.0M in total across 4 funding rounds.
UNITY Biotechnology has raised $212.0M across 4 funding rounds. Most recently, it raised $55.0M Series C in March 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2018 | $55M Series C | — | Venrock, Vivo Capital, 6 Dimensions Capital, Altitude Life Science Ventures, ARCH Venture Partners, EcoR1 Capital, Fidelity Management & Research Company, Founders Fund, Invus Opportunities, Longevity Fund, Partner Fund Management, Pivotal Alpha Limited | Announced |
| Aug 1, 2017 | $35M Series B | ARCH Venture Partners, Venrock, Fidelity Management & Research Company, Partner Fund Management | Foundry Group, High Alpha, LOI Venture, Menlo Ventures, Vivo Capital, Rudy Gadre, Bezos Expeditions, Cycad Group, Founders Fund, Invus Opportunities, Mayo Clinic, Pivotal Alpha Limited, Three Lakes Partners, Vulcan Capital, WuXi AppTec | Announced |
| Oct 1, 2016 | $120M Series B | — | ARCH Venture Partners, Foundry Group, High Alpha, LOI Venture, Menlo Ventures, Venrock, Vivo Capital, Rudy Gadre, Mayo Clinic, WuXi AppTec | Announced |
| Dec 1, 2014 | $2M Series A | — | Venrock, Vivo Capital | Announced |
Unity Biotechnology is a clinical-stage biotechnology company developing novel therapeutics targeting cellular senescence to treat age-related diseases like osteoarthritis, age-related macular degeneration, and diabetic macular edema.[1][2] It serves patients suffering from debilitating conditions of aging by creating senolytic drugs that eliminate senescent cells—non-dividing but metabolically active cells driving chronic inflammation and tissue dysfunction—shifting treatment from symptom management to root causes.[1][2] The company's pipeline includes lead candidates like foselutoclax (Bcl-xL inhibitor) in Phase 2 for diabetic macular edema, and preclinical programs such as UBB-2048 (Tie-2 x VEGF-A bispecific) for retinal disorders and UBX-2089 for cognition disorders, reflecting strong momentum in senolytic innovation amid a growing regenerative medicine market.[1][5]
Unity Biotechnology was founded in 2009 (with key activities ramping up by 2011) in Brisbane, CA, by a team including co-founder Michael Davidson, who advanced concepts like α-Klotho for longevity.[3][1][5] The idea emerged from foundational research on aging biology, particularly cellular senescence as a root cause of age-related diseases, enabled by partnerships with leading academics and scientists dedicated to translating aging science into therapies.[2] Early traction included building a broad pipeline over six years pre-IPO, culminating in a $85 million public offering on May 2, 2018, at $17 per share, despite a modest -2.1% first-day return, and initiating its first clinical study in 2018.[2][3] Pivotal moments involved securing collaborations and recruiting top-tier talent to pioneer senolytic medicines.[1][2]
Unity rides the longevity biotech trend, targeting the expanding senolytics market as global populations age and demand shifts to preventive, cellular-level interventions over palliative care.[1][2][6] Timing aligns with surging interest in aging biology—post-2010s senescence discoveries—fueled by market forces like rising chronic disease prevalence and biopharma investments in healthspan extension.[1][7] It influences the ecosystem by validating senescent cell clearance as a therapeutic paradigm, inspiring partnerships, and advancing clinical proof-of-concept in high-need areas like ophthalmology and cognition, potentially accelerating broader adoption of anti-aging modalities.[1][2][5]
Unity's next milestones include advancing foselutoclax through Phase 2 readouts and preclinical assets like UBB-2048 toward clinic, with earnings on August 4, 2025, offering visibility into momentum amid a negative P/E ratio signaling growth investments.[1][5] Trends like AI-driven drug discovery, systemic senolytics, and longevity funding will shape its path, potentially evolving Unity from niche pioneer to healthspan leader if trials succeed. As a senolytics trailblazer, it embodies the shift from treating age-related frailty to eradicating its cellular roots.[1][2]
UNITY Biotechnology has raised $212.0M in total across 4 funding rounds.
UNITY Biotechnology's investors include Venrock, Vivo Capital, 6 Dimensions Capital, Altitude Life Science Ventures, ARCH Venture Partners, EcoR1 Capital, Fidelity Management & Research Company, Founders Fund, Invus Opportunities, Longevity Fund, Partner Fund Management, Pivotal Alpha Limited.
